Quince Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 11, 2026
QNCX$31.73+8.1%Stored close · as of Oct 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Balance Sheets (Unaudited)
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands except share amounts)
| March 31, 2026 | December 31, 2025 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $18,163 | $5,809 |
| Short-term investments | — | 11,943 |
| Prepaid expenses and other current assets | 7,417 | 5,144 |
| Total current assets | 25,580 | 22,896 |
| Property and equipment, net | 550 | 595 |
| Operating lease right-of-use assets | 415 | 453 |
| Intangible assets | — | 67,819 |
| Other assets | 78 | 1,760 |
| Total assets | $26,623 | $93,523 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||
| Current liabilities: | ||
| Accounts payable | $5,392 | $2,223 |
| Accrued expenses and other current liabilities | 3,376 | 10,608 |
| Current portion of debt | — | 18,026 |
| Short-term contingent consideration | — | 12,369 |
| Total current liabilities | 8,768 | 43,226 |
| Long-term operating lease liabilities | 293 | 330 |
| Long-term contingent consideration | — | 51,961 |
| Warrant liabilities | 694 | 32,150 |
| Other long-term liabilities | 1,196 | 1,570 |
| Total liabilities | 10,951 | 129,237 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.001 par value, 10,000,000 authorized, no shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.001 par value, 250,000,000 shares authorized, 13,790,794 and 5,572,529 issued and outstanding as of March 31, 2026 and December 31, 2025, respectively(1) | 14 | 6 |
| Additional paid in capital(1) | 435,587 | 418,981 |
| Accumulated other comprehensive income | 4,610 | 5,750 |
| Accumulated deficit | (424,539) | (460,451) |
| Total stockholders’ equity (deficit) | 15,672 | (35,714) |
| Total liabilities and stockholders’ equity (deficit) | $26,623 | $93,523 |
(1) Adjusted prior period common stock and additional paid-in-capital to reflect the 1-for-10 reverse stock split effected on April 10, 2026.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.